Can-Fite BioPharma Ltd. SEC Filings

CANF NYSE

Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Can-Fite BioPharma’s risk-heavy biotech disclosures can feel like decoding lab notes. Clinical trial timelines, dilution clauses and revenue-sharing terms hide deep in each page. That complexity is why investors search for “Can-Fite BioPharma SEC filings explained simply” and “understanding Can-Fite BioPharma SEC documents with AI.”

Stock Titan turns that challenge into clarity. Our AI reads every new 10-K, 10-Q and 8-K the moment it posts to EDGAR, then highlights what matters for a clinical-stage company: R&D burn rate, Phase III milestones, cash runway and licensing revenue. Need the “Can-Fite BioPharma quarterly earnings report 10-Q filing” or an instant view of “Can-Fite BioPharma 8-K material events explained”? It’s one click away, already summarized in plain English.

Executive moves move micro-cap prices. Track “Can-Fite BioPharma insider trading Form 4 transactions” with real-time alerts. Our dashboard links every “Can-Fite BioPharma executive stock transactions Form 4” to trial announcements so you spot patterns early. Looking for board pay details? The latest “Can-Fite BioPharma proxy statement executive compensation” is tagged and translated into transparent tables.

Whether you’re comparing pipeline spending across quarters, assessing dilution risk, or needing a “Can-Fite BioPharma annual report 10-K simplified,” Stock Titan delivers. AI-powered summaries, expert context, and comprehensive coverage of all filings—so you spend minutes, not hours, on “Can-Fite BioPharma earnings report filing analysis.”

06/23/2025 04:15 PM

Filing

[6-K] Can-Fite BioPharma Ltd. American Current Report (Foreign Issuer)

Rhea-AI Summary

Can-Fite BioPharma announced the adjournment of its Annual General Meeting of Shareholders originally scheduled for June 23, 2025, due to lack of quorum. The meeting has been rescheduled for June 30, 2025, at 3:00 p.m. Israel time and will be held at the company's offices in Ramat Gan, Israel.

The Form 6-K was signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer of the company. This regulatory filing fulfills the company's obligation to report material events to shareholders under Securities Exchange Act requirements.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Can-Fite BioPharma Ltd. (CANF)?

The current stock price of Can-Fite BioPharma Ltd. (CANF) is $1.04 as of June 28, 2025.

What is the market cap of Can-Fite BioPharma Ltd. (CANF)?

The market cap of Can-Fite BioPharma Ltd. (CANF) is approximately 13.6M.

What is the primary focus of Can-Fite BioPharma Ltd.?

Can-Fite BioPharma Ltd. focuses on developing innovative, orally bioavailable small molecule therapeutic products targeting the A3 adenosine receptor for the treatment of cancer, liver, and inflammatory diseases.

How does Can-Fite differentiate its technology from other biotech companies?

The company differentiates itself through its proprietary A3AR platform. This technology allows for targeted therapy by exploiting the differential expression of the receptor in diseased versus normal cells, which contributes to an improved safety profile.

What are the key drug candidates in Can-Fite’s pipeline?

Can-Fite’s pipeline includes drug candidates such as Piclidenoson and Namodenoson. Piclidenoson is being studied for psoriasis, while Namodenoson is evaluated for hepatocellular carcinoma and conditions related to liver disease.

What therapeutic areas does Can-Fite primarily target?

The company primarily targets oncology, liver-related diseases, and inflammatory disorders, leveraging its research in the A3 adenosine receptor pathway to address these conditions.

How does the company maintain its clinical development programs?

Can-Fite supports its clinical programs through strategic financing initiatives such as warrant exercises and capital restructuring, ensuring sufficient funds for the advancement of its drug candidates through clinical trials.

What role does the A3 adenosine receptor play in Can-Fite’s approach?

The A3 adenosine receptor is central to Can-Fite’s approach as it is highly expressed in diseased cells. Targeting this receptor allows for more selective therapeutic effects, reducing potential harm to normal cells and thereby supporting a favorable safety profile.

How is Can-Fite positioned within the competitive biopharmaceutical landscape?

Can-Fite is recognized for its specialized approach using the A3AR platform, which distinguishes it from competitors through targeted drug development. Its focus on critical conditions such as cancer and liver diseases positions it within segments that demand innovative therapeutic solutions.

Are there any additional benefits associated with Can-Fite’s drug candidates?

Yes, some of Can-Fite’s candidates, such as Namodenoson, offer dual benefits. Besides their primary anti-cancer activity, they also provide liver-protective effects by reducing inflammation, fat accumulation, and fibrosis, enhancing their therapeutic appeal.